CAMBRIDGE, Mass. and CHICAGO, Dec. 19, 2023 /PRNewswire/ -- Shorla Oncology ('Shorla'), a U.S.-Ireland specialty pharmaceutical company, and EVERSANA®, a leading provider of commercialization services to the life science industry, today announced the commercial launch of JYLAMVO (methotrexate) oral solution, the first and only oral methotrexate solution approved in the United States for use in adults. JYLAMVO has been shown to have a sweet, palatable taste1,2*and is approved to treat adults with acute lymphoblastic leukemia as part of a combination chemotherapy maintenance regimen; mycosis fungoides (cutaneous T-cell lymphoma) as a single agent or as part of a combination chemotherapy regimen; relapsed or refractory non-Hodgkin lymphomas as part of a metronomic combination chemotherapy regimen; rheumatoid arthritis; and severe psoriasis.
LONDON, Dec. 14, 2023 /PRNewswire/ -- Driven to transform and unify commercialisation services for pharmaceutical brands entering or expanding into Europe, EVERSANA, a leading provider of commercialisation services to the life sciences industry, has united seven leading organizations to form the Global Alliance for Pharma Solutions (GAPS).
CHICAGO and SALERNO, Italy, Oct. 11, 2023 /PRNewswire/ -- EVERSANA, a leading provider of global commercial services to the life sciences industry, today announced the acquisition of Healthware Group, a full-service agency and innovation consultancy headquartered in Salerno, Italy. The acquisition immediately expands EVERSANA's European operations and worldwide capabilities to help pharmaceutical, medical device, and emerging biotech companies globally launch products, expand market access, or solve unique geographic and market-specific challenges.
CHICAGO, Sept. 18, 2023 /PRNewswire/ -- EVERSANA®, a leading provider of commercialization services to the global life sciences industry, today announced a powerful advancement in its patient support services and unveiled its new proprietary electronic benefits verification (eBV) and electronic prior authorization (ePA) platform called ACTICS® eAccess.
CHICAGO, Sept. 6, 2023 /PRNewswire/ -- EVERSANA, a leading provider of commercial services to the global life sciences industry, today announced the appointment of Ryan Sparks as the company's Chief Information Officer. A proven technology leader and decorated military veteran, Sparks is responsible for the global enterprise's IT operations across 25 locations, serving more than 650 pharmaceutical and biotechnology companies worldwide.
SOLANA BEACH, Calif., and CHICAGO, July 25, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI)...
With Xspray Pharma and Eversana’s cancer med hitting a regulatory setback, a launch in the second half of 2023 now looks unlikely. That’s good news for Bristol Myers Squibb, which has secured a few more competition-free months for its aging leukemia blockbuster Sprycel.
CHICAGO, June 5, 2023 /PRNewswire/ -- EVERSANA, a leading provider of commercial services to the global life sciences industry, today announced that its agency network, EVERSANA INTOUCH, has been named a five-category winner at the 2023 Clio Health Awards.
BEIJING, June 1, 2023 /PRNewswire/ -- EVERSANA®, a leading provider of commercialization services to the global life sciences industry, today announced that it has established a strategic alliance with the China Resources Pharmaceutical Commercial Group, a leading pharmaceutical distribution enterprise based in Beijing.
STOCKHOLM, Feb. 23, 2023 /PRNewswire/ -- Xspray Pharma AB, (NASDAQ Stockholm: XSPRAY) has signed an agreement with EVERSANA® to support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL). While maintaining financial and strategic control, Xspray Pharma will grant EVERSANA exclusive commercialization access to support its Dasynoc launch, aimed at the second half of 2023. Dasynoc, pending FDA-approval and legal conditions, will be a new and differentiated treatment option for CML and ALL patients, entering the $3.5 billion commercial market for Tyrosine Kinase Inhibitors in the United States – a market that has grown by nearly 5% in the last year alone.